Menaflex: The Winding Road To Rescission
This article was originally published in The Gray Sheet
Executive Summary
FDA announced on Oct. 14 that it plans to seek rescission of ReGen Biologics' 510(k) for the Menaflex collagen scaffold. The device has already experienced many twists and turns along the regulatory pathway, as this timeline suggests: